PDS Biotechnology

PDS Biotechnology

Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

$41.6M

Market Cap • 9/29/2026

2009

(17 years)

Founded

2015

(11 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

41,6M

EV

40,3M

EV/Revenue

0

EV/EBITDA

-1,5

EV/EBIT

-1,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-25%

Total Yield

-25%

Payout

0%

Retained Earnings

-233,7M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

2,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

11,6%

CAGR Net Income 5Y

23,8%

CAGR EPS 5Y

3,5%

CAGR OCF 5Y

13,9%

Leverage

N.D./EBITDA

0

Debt/Equity

0%

Current Ratio

0,6

Quick Ratio

0,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium